A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management

被引:3
|
作者
Micheletto, Claudio [1 ]
Braido, Fulvio [2 ]
Contoli, Marco [3 ]
Di Marco, Fabiano [4 ]
Santus, Pierachille [5 ]
机构
[1] Azienda Osped Univ Integrata, Resp Unit, Piazzale Stefani 1, I-37122 Verona, Italy
[2] Univ Genoa, Azienda Policlin IRCCS San Martino, Dept Internal Med Resp Dis & Allergy Clin, Genoa, Italy
[3] Univ Ferrara, Dept Med Sci, Ferrara, Italy
[4] Univ Milan, Dept Hlth Sci, Resp Unit, Papa Giovanni XXIII Hosp, Bergamo, Italy
[5] Univ Milan, ASST Fatebenefratelli, Luigi Sacco Univ Hosp, Dept Hlth Sci,Pulm Unit, Milan, Italy
来源
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2019年 / 14卷
关键词
COPD; exacerbation; inhaled corticosteroids; LABA; LAMA; deprescribing; OBSTRUCTIVE PULMONARY-DISEASE; BLOOD EOSINOPHILS; COMBINATION THERAPY; AIRWAY EOSINOPHILIA; SPUTUM EOSINOPHILIA; FLUTICASONE FUROATE; CHRONIC-BRONCHITIS; PARALLEL-GROUP; DOUBLE-BLIND; EXACERBATIONS;
D O I
10.2147/COPD.S216059
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
While chronic obstructive pulmonary disease (COPD) continues to be a major cause of morbidity and mortality, pharmacological therapy has a definite benefit on symptoms as well as the frequency and severity of exacerbations, and general health. The most recent Global Initiative for Obstructive Lung Disease (GOLD) guidelines recommend triple therapy (long-acting beta2 agonists [LABA] + long-acting muscarinic antagonists [LAMA] + inhaled corticosteroids [ICS]) only for patients with exacerbations, elevated eosinophils, and without control using a LABA/LAMA or ICS/LABA combination. Long-term monotherapy with ICS is not currently recommended, but may be considered in association with LABAs in patients with a history of exacerbations and elevated eosinophils in spite of appropriate treatment with long-acting bronchodilators. However, long-term use of ICS in combination therapy has been associated with adverse effects, even if widely used in routine management for decades. The available evidence suggests that ICS can be rationally discontinued in patients with stable disease and is not likely to have unfavorable effects on lung function, overall health, or be associated with a greater risk of exacerbations. Indeed, it is widely accepted that ICS therapy should be limited to a small proportion of patients after careful assessment of the individual risk-benefit profile. Unfortunately, however, there are no international recommendations that provide specific guidance or a protocol for withdrawal of ICS. Herein, the available evidence on the use of ICS is reviewed and an easy to use tool is proposed that can provide clinicians with a simple management scheme to guide the most appropriate therapy for management of COPD and use of ICS. In management of COPD, a highly personalized approach is advocated so that the most appropriate therapy for each individual patient can be selected.
引用
收藏
页码:2185 / 2193
页数:9
相关论文
共 20 条
  • [1] Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms
    Avdeev, Sergey
    Aisanov, Zaurbek
    Arkhipov, Vladimir
    Belevskiy, Andrey
    Leshchenko, Igor
    Ovcharenko, Svetlana
    Shmelev, Evgeny
    Miravitlles, Marc
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2019, 14 : 1267 - 1280
  • [2] Withdrawal of Inhaled Corticosteroids in Patients with COPD - A Prospective Observational Study
    Nielsen, Anne Orholm
    Hilberg, Ole
    Jensen, Jens Ulrik Staehr
    Kristensen, Steffen Helmer
    Frolund, Jannie Christina
    Langkilde, Pernille Kolholt
    Lokke, Anders
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2021, 16 : 807 - 815
  • [3] Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)
    Rossi, Andrea
    Guerriero, Massimo
    Corrado, Antonio
    RESPIRATORY RESEARCH, 2014, 15
  • [4] A descriptive cohort study of withdrawal from inhaled corticosteroids in COPD patients
    Patel, Smit
    Dickinson, Scott
    Morris, Kevin
    Ashdown, Helen F.
    Chalmers, James D.
    NPJ PRIMARY CARE RESPIRATORY MEDICINE, 2022, 32 (01)
  • [5] Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale
    Magnussen, Helgo
    Watz, Henrik
    Kirsten, Anne
    Decramer, Marc
    Dahl, Ronald
    Calverley, Peter M. A.
    Towse, Lesley
    Finnigan, Helen
    Tetzlaff, Kay
    Disse, Bernd
    RESPIRATORY MEDICINE, 2014, 108 (04) : 593 - 599
  • [6] The impact of step se withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study
    Magnussen, Helgo
    Chanez, Pascal
    Dahl, Ronald
    Decramer, Marc
    Disse, Bernd
    Finnigan, Helen
    Kirsten, Anne
    Rodriguez-Roisin, Roberto
    Tetzlaff, Kay
    Towse, Lesley
    Watz, Henrik
    Wouters, Emiel
    Calverley, Peter
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [7] Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice
    Kaplan, Alan G.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2015, 10 : 2535 - 2548
  • [8] Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study
    Magnussen, Helgo
    Lucas, Sarah
    Lapperre, Therese
    Quint, Jennifer K.
    Dandurand, Ronald J.
    Roche, Nicolas
    Papi, Alberto
    Price, David
    Miravitlles, Marc
    RESPIRATORY RESEARCH, 2021, 22 (01)
  • [9] Withdrawal of Inhaled Corticosteroids from Patients with COPD; Effect on Exacerbation Frequency and Lung Function: A Systematic Review
    Georgiou, Andrea
    Ramesh, Reshma
    Schofield, Peter
    White, Patrick
    Harries, Timothy H.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2024, 19 : 1403 - 1419
  • [10] Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)
    Andrea Rossi
    Massimo Guerriero
    Antonio Corrado
    Respiratory Research, 15